| Objective:The final purpose of the study was to find further verification of the effectivity and security of Quzao lipid-lowering capsules in patients with primary hyperlipidemia which classified as intermin-gled phlegm and blood stasis syndrome,and to provide reasonable evidence for Quzao lipid-lowering of capsules in III stage of further clinical study.Methods:From the first hospital of Heilongjiang university of Chinese medicine,we selected 30 qualified patients and devided into 2 groups:the treatment group and the control group,by the method of random, double-blind,placebo parallel control.The patients of treatment group taked three Quzao lipid-lowering capsules each time,and three times a day.The concrol group taked three analogic Quzao lipid-lowering capsules each time,and three times a day.All the patients were observed for 12 weeks.We analysised and compared the difference of efficacy indicators (TG,HDL-C) and security index in liver function as ALT,AST,ALP before the treatment and after the treatment.Results:1. Efficacy indicators:Compared with before treatment,TG level were decreased and HDL-C level were increased in the treatment group after the trial,the difference was statistically significant(P<0.05). Compared with the control group after treatment,TG level were decreased and HDL-C level were increased in the treatment group after the trial,the difference was statistically significant(P<0.05).2.Safety indicators:Compared with before treatment,there is no obviously abnormal in ALT,AST,ALP in two groups after the treatment, which is no statistically significance difference(P>0.05).Conclusion:1. The patients who have primary hyperlipidemia which classified as intermin-gled phlegm and blood stasis syndrome can be decreased TG level and increased HDL-C level in blood by taking Quzao lipid-lowering capsules.2.During the treatment of Quzao lipid-lowering capsules in our center,we did not find obviously side effects and adverse reactions. |
PDF Full Text Request